Semaglutide and Liraglutide Protect Heart and Kidneys Regardless of Blood Pressure Level
Post-hoc analysis of 12,637 patients shows liraglutide and semaglutide reduce cardiovascular events and kidney disease in type 2 diabetes patients regardless of baseline blood pressure.
Quick Facts
What This Study Found
No statistical heterogeneity in cardiovascular (MACE) or nephropathy outcomes across blood pressure categories for either liraglutide or semaglutide vs placebo.
Key Numbers
LEADER: 9,340 patients; SUSTAIN 6: 3,297; 70-74% hypertensive; no heterogeneity for MACE or nephropathy across BP categories
How They Did This
Post-hoc analysis of two randomized controlled trials (LEADER and SUSTAIN 6) using Cox proportional hazards models adjusted for cardiorenal risk factors, stratified by baseline BP category.
Why This Research Matters
Clinicians can prescribe GLP-1 drugs for cardiovascular and kidney protection in type 2 diabetes without worrying that high or low blood pressure will negate the benefits.
The Bigger Picture
GLP-1 receptor agonists are increasingly recognized as cardiovascular protective drugs beyond their glucose-lowering effects. This analysis removes blood pressure as a concern when prescribing them.
What This Study Doesn't Tell Us
Post-hoc analysis (not pre-specified); BP measured at baseline only (not longitudinally); separate trial analyses (not pooled); may lack power for some subgroups.
Questions This Raises
- ?Do GLP-1 agonists actually lower blood pressure as part of their cardioprotective mechanism?
- ?Would these results hold in patients with resistant hypertension?
- ?Is there a combined benefit of GLP-1 agonists plus intensive BP control?
Trust & Context
- Key Stat:
- 12,637 patients Combined LEADER and SUSTAIN 6 analysis showing consistent cardiorenal benefits across all BP categories
- Evidence Grade:
- Strong — large-scale post-hoc analysis of two major randomized controlled trials with robust statistical methodology.
- Study Age:
- Published in 2020; semaglutide cardiovascular evidence has strengthened further with SELECT trial results (2023).
- Original Title:
- The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
- Published In:
- Diabetes, obesity & metabolism, 22(9), 1690-1695 (2020)
- Authors:
- Leiter, Lawrence A(4), Bain, Stephen C(9), Bhatt, Deepak L, Buse, John B, Mazer, C David, Pratley, Richard E, Rasmussen, Søren, Ripa, Maria Sejersten, Vrazic, Hrvoje, Verma, Subodh
- Database ID:
- RPEP-04940
Evidence Hierarchy
Frequently Asked Questions
Should I avoid semaglutide if I have high blood pressure?
No — this analysis of over 12,000 patients found the cardiovascular and kidney benefits were consistent regardless of blood pressure level.
What is MACE?
Major Adverse Cardiovascular Events — typically includes heart attack, stroke, and cardiovascular death. It's the standard measure of cardiovascular safety and benefit in drug trials.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04940APA
Leiter, Lawrence A; Bain, Stephen C; Bhatt, Deepak L; Buse, John B; Mazer, C David; Pratley, Richard E; Rasmussen, Søren; Ripa, Maria Sejersten; Vrazic, Hrvoje; Verma, Subodh. (2020). The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.. Diabetes, obesity & metabolism, 22(9), 1690-1695. https://doi.org/10.1111/dom.14079
MLA
Leiter, Lawrence A, et al. "The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.." Diabetes, 2020. https://doi.org/10.1111/dom.14079
RethinkPeptides
RethinkPeptides Research Database. "The effect of glucagon-like peptide-1 receptor agonists lira..." RPEP-04940. Retrieved from https://rethinkpeptides.com/research/leiter-2020-the-effect-of-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.